-
-
Toggle navigation
Frontiers reaches 6.4 on Journal Impact Factors
in Oncology |
|
Submit your manuscript
Scope
A large number of scientific teams worldwide are working on research questions related to lung cancer, mesothelioma, esophageal cancer, sarcoma and cancer that has metastasized to the chest. The process of publishing results, both positive and negative, still remains inflexible and very slow, and Thoracic Oncology aims to address these challenges directly, by providing an open access, equal opportunity publishing platform for scientists. Lung cancer, the most common type of cancer in the world, is the leading cause of cancer death in adults, and poses one of the major medical science challenges in the coming decades. The heterogeneity of non-small cell lung cancer at diagnosis makes this cancer a particularly complex and unpredictable disease. Multiple new molecular pathways associated with the development of lung cancer are reported every year, and these offer myriad potential treatment targets. Very few of these potential molecular targets, however, reach the registration step. There are several reasons for this, including i) a lack of predominant pathway alterations, ii) a multiplicity of predominant alterations, iii) a lack of specificity in target molecules, and iv) sub-optimal registration strategies that is often related to excessive speed in the design of a registration process. The importance of publishing results in a fair, open, and timely manner is why Frontiers in Oncology, an online publication with an efficient review process, is especially valuable to the scientific and medical research community. Thoracic Oncology reaches out to extend this opportunity to the many basic and translational researchers work in the growing fields related to understanding and treating thoracic malignancies.Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Thoracic Oncology welcomes submissions of the following article types: Book Review, Case Report, Clinical Trial, Correction, Data Report, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology Report.
All manuscripts must be submitted directly to the section Thoracic Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Thoracic Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01